Call for Abstract

International Epigenetics and Epitranscriptomics Conference, will be organized around the theme “The Evolving Landscape of Epigenetic Research”

Epitranscriptomics 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Epitranscriptomics 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Animal epigenetics
  • Track 1-2Single cell epigenetics
  • Track 1-3Epigenetic therapy
  • Track 1-4Toxicoepigenetics
  • Track 1-5Single cell epigenetics
  • Track 1-6Autoimmunity and epigenetics
  • Track 1-7Biomarkers for blood cancer
  • Track 2-1DNA methylation
  • Track 2-2Histone modification
  • Track 2-3Gene silencing
  • Track 2-4Epigenomics
  • Track 2-5cytosine methylation
  • Track 2-6Mitotic gene bookmarking
  • Track 2-7Hydroxymethylation
  • Track 2-8Oxidative Demethylation
  • Track 3-1Gene expression
  • Track 3-2clonal genome evolution
  • Track 3-3 epigenetic variation
  • Track 3-4Homo and Hetro Chromosome
  • Track 3-5Chromosomal Segregation
  • Track 4-1Chip sequencing
  • Track 4-2Epigenetics inhibitors and emerging targets
  • Track 4-3Gene control by metabolism
  • Track 4-4Higher order chromatin
  • Track 5-1Carcinogen evaluation
  • Track 5-2Epigenetic effects of air pollutant exposure
  • Track 5-3Ecological epigenetics
  • Track 5-4Infections and microbiome
  • Track 5-5Early life exposures
  • Track 6-1Cardiomyopathy
  • Track 6-2Hypertensive heart disease
  • Track 6-3Heart failure
  • Track 6-4Congenital heart disease
  • Track 6-5Rheumatic heart disease
  • Track 6-6Pulmonary heart disease
  • Track 7-1Irinotecan
  • Track 7-2serotonin transporter gene
  • Track 7-3Genomic DNA and mRNA
  • Track 8-1Evolutionary and population genetics
  • Track 9-1Cancer epigenetics
  • Track 9-2Epigenetics and allergic disorders
  • Track 9-3Epigenetics of human infectious diseases
  • Track 9-4Fragile X syndrome
  • Track 9-5 Angelman’s syndrome
  • Track 9-6 facial anomalies syndrome
  • Track 9-7Epilepsy

  • Track 10-1Epigenetics and ethics
  • Track 10-2New epigenetic phenomena
  • Track 10-3Epigenetics yoga therapy
  • Track 10-4Combating Diseases with Epigenetics Therapy
  • Track 10-5Case reports on molecular biomarkers
  • Track 11-1Crop epigenetics: hybridization and heterosis
  • Track 11-2Natural variation and ecological epigenetics
  • Track 11-3Stress-induced epigenetics changes
  • Track 11-4Epigenetics regulation of host-pathogen interactions
  • Track 11-5Heritability of epigenetic marks
  • Track 11-6 DNA Methylation in Plants
  • Track 12-1post-translational modifications
  • Track 12-2 histone variants
  • Track 12-3stem or progenitor cells
  • Track 12-4controlling gene expression
  • Track 12-5Neoplastic transformations
  • Track 13-1Epigenetic dysregulation in cancer
  • Track 13-2Epigenetics in immune cells
  • Track 13-3Immunological disorders
  • Track 13-4Methylation inhibiting drugs
  • Track 13-5Protein methyltransferase inhibitors
  • Track 13-6Future Direction of Epigenetics Drugs
  • Track 14-1embryonic and adult stem cells
  • Track 14-2mesenchymal stem cells (MSCs)
  • Track 14-3neural stem cells (NSCs)
  • Track 14-4induced pluripotent stem cells (iPSCs)
  • Track 15-1Gene Ontology
  • Track 15-2RNA editing
  • Track 15-3Psuedourylation
  • Track 15-4RNA methylation
  • Track 15-5RNA modification mapping
  • Track 15-6RNA adenylation & RNA uridylation
  • Track 15-7 RNA modification in disease
  • Track 16-1Single nucleotide methods
  • Track 16-2DNA mutations
  • Track 16-3APOBEC and ADAR RNA Editing
  • Track 16-4Single molecule sequencing
  • Track 16-5m6A-sequencing
  • Track 17-1RNA immunoprecipitation (RIP)‐based methods
  • Track 17-2NGS‐based RNA modification techniques
  • Track 17-3post‐transcriptional modifications of RNA
  • Track 17-4RNA-mediated gene regulation
  • Track 17-5microRNA
  • Track 17-6RNA interference
  • Track 18-1Breast cancer
  • Track 18-2Ovarian cancer
  • Track 18-3Malignant rhabdoid tumors
  • Track 18-4genetic alterations in cancers
  • Track 18-5Urological cancers
  • Track 18-6Testis cancers
  • Track 18-7Genetic biomarkers
  • Track 18-8Biomarkers for lung cancer
  • Track 19-1Lungs Cancer
  • Track 19-2Mental retardation disorders
  • Track 19-3Immunity & related disorders
  • Track 19-4Neuropsychiatric disorders
  • Track 19-5Longevity and aging
  • Track 19-6Aneuploidy
  • Track 19-7Primary head and neck